Our mission is to transform the clinical management of patients with cancer by developing and delivering innovative molecular imaging technologies to address unmet clinical needs, and reliably inform diagnosis and treatment decisions.
Our team is made up of industry leaders and experts in the field of radiopharmaceutical development and commercialisation.
Blue Earth Diagnostics is backed by Syncona Limited, a leading FTSE250 healthcare company focused on investing in and building global leaders in life science.
Find out how this technique works
Find out about prostate cancer
Cellular mechanisms for amino acid transport
Our research focus
Who we are
Who we work with
See how you can join the team
Where we are going to be
Expanded facility positions the company for future growth OXFORD, April 12, UK –, 2018 –Blue Earth Diagnostics, a leading molecular imaging diagnostics company, today announced the opening of its...
Read More ›– NCCN Guidelines aim to improve quality, effectiveness and efficiency of cancer care – BURLINGTON, Mass. and OXFORD, UK – February 20, 2018 – Blue Earth Diagnostics, a molecular...
Read More ›– Company updates that F-18 fluciclovine (Axumin®) PET/CT now listed in American College of Radiology Appropriateness Criteria® for the Post-Treatment Follow-up of Prostate Cancer – BURLINGTON, Mass. and OXFORD,...
Read More ›Oxford, UK – October 10, 2017 – Blue Earth Diagnostics, a molecular imaging diagnostics company, and Seibersdorf Laboratories, a leading developer and manufacturer of radiopharmaceuticals, today announced that they...
Read More ›